|
Volumn 13, Issue 6, 2012, Pages 568-569
|
Personalised medicine in nasopharyngeal cancer
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
MICRORNA;
PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;
VIRUS DNA;
WNT PROTEIN;
CANCER CLASSIFICATION;
CANCER PROGNOSIS;
CANCER RADIOTHERAPY;
CANCER STAGING;
CANCER SURVIVAL;
CERVICAL LYMPH NODE;
CHINESE MEDICINE;
CLINICAL FEATURE;
CORRELATION ANALYSIS;
DISEASE FREE SURVIVAL;
DISTANT METASTASIS;
EPSTEIN BARR VIRUS;
GENE DOSAGE;
GENOTYPE PHENOTYPE CORRELATION;
HIGH RISK PATIENT;
HUMAN;
LETTER;
LYMPH NODE METASTASIS;
MEDICAL DECISION MAKING;
MOLECULARLY TARGETED THERAPY;
NASOPHARYNX CANCER;
OVERALL SURVIVAL;
PATIENT IDENTIFICATION;
PATIENT SELECTION;
PERSONALIZED MEDICINE;
PREDICTION;
PRIORITY JOURNAL;
PTEN GENE;
RADIATION DOSE;
RADIOSENSITIVITY;
RISK ASSESSMENT;
SIGNAL TRANSDUCTION;
SKULL BASE FRACTURE;
TREATMENT FAILURE;
TREATMENT PLANNING;
TUMOR SUPPRESSOR GENE;
VIRUS CARCINOGENESIS;
FEMALE;
GENE EXPRESSION PROFILING;
GENE EXPRESSION REGULATION, NEOPLASTIC;
HUMANS;
MALE;
MICRORNAS;
NASOPHARYNGEAL NEOPLASMS;
TUMOR MARKERS, BIOLOGICAL;
|
EID: 84861577316
PISSN: 14702045
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/S1470-2045(12)70115-8 Document Type: Letter |
Times cited : (4)
|
References (7)
|